In This Article:
As Japan’s stock markets experience a downturn, with the Nikkei 225 Index down 5.8% and the broader TOPIX Index registering a 4.2% loss, investors are increasingly looking for opportunities in small-cap stocks that may offer resilience and growth potential amid broader market volatility. In this environment, identifying companies with strong fundamentals and unique market positions can be crucial for uncovering hidden gems.
Top 10 Undiscovered Gems With Strong Fundamentals In Japan
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Ryoyu Systems | NA | 1.08% | 8.08% | ★★★★★★ |
| NJS | NA | 4.97% | 5.30% | ★★★★★★ |
| Kanda HoldingsLtd | 30.47% | 4.35% | 18.02% | ★★★★★★ |
| Poppins | 39.80% | 8.36% | -7.40% | ★★★★★★ |
| Ad-Sol Nissin | NA | 4.02% | 7.90% | ★★★★★★ |
| Otec | 9.81% | 2.32% | -1.39% | ★★★★★★ |
| NPR-Riken | 15.31% | 10.00% | 44.55% | ★★★★★☆ |
| Toho | 82.16% | 1.83% | 47.38% | ★★★★★☆ |
| AJIS | 0.69% | 0.07% | -12.44% | ★★★★★☆ |
| Pharma Foods International | 191.14% | 33.83% | 23.46% | ★★★★★☆ |
Below we spotlight a couple of our favorites from our exclusive screener.
MEISEI INDUSTRIALLtd
Simply Wall St Value Rating: ★★★★★★
Overview: MEISEI INDUSTRIAL Co., Ltd. operates as a construction works company in Japan and internationally with a market cap of ¥57.43 billion.
Operations: MEISEI INDUSTRIAL Co., Ltd. generates revenue primarily from its Construction Work segment (¥55.55 billion) and Boiler Business (¥7.45 billion).
MEISEI INDUSTRIAL Ltd., a small cap, has shown impressive growth with earnings increasing by 44.4% over the past year, outpacing the Construction industry’s 25.5%. The company's debt to equity ratio improved from 2.1% to 1.2% in five years, reflecting prudent financial management. Trading at 54.4% below estimated fair value suggests potential for significant upside. With high-quality earnings and more cash than total debt, MEISEI seems well-positioned for continued stability and growth in its sector.
KYORIN Pharmaceutical
Simply Wall St Value Rating: ★★★★★☆
Overview: KYORIN Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells ethical and generic drugs in Japan and internationally with a market cap of ¥88.13 billion.
Operations: KYORIN Pharmaceutical generates revenue primarily from its pharmaceutical business, which reported ¥120.10 billion in revenue. The company's net profit margin stands at 5.23%.
Kyorin Pharmaceutical, a small-cap player in the Japanese market, has shown robust earnings growth of 31.2% over the past year, outpacing the industry average of 8.6%. The company's debt to equity ratio improved from 19.4% to 15.9% over five years, indicating prudent financial management. Trading at a price-to-earnings ratio of 15.9x compared to the industry average of 17.6x suggests it offers good value for investors looking at pharmaceuticals in Japan.